Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 Biomarker disease BEFREE PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. 31785230 2020
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 Biomarker disease BEFREE Disruption of IQGAP1-scaffolded PI3K/AKT signaling reduced HNC cell survival. 31597661 2020
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 Biomarker disease BEFREE We found that PI3K regulatory subunit p85 was predominantly phosphorylated in radioresistant head and neck cancer cell line (HN31), which showed resistance to PI3K inhibitors. 29496059 2018
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 Biomarker disease BEFREE Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. 29440171 2018
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 AlteredExpression disease BEFREE Moreover, MSC-CM promoted the expression of POSTN and POSTN promoted HNC progression through the activation of the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway. 29284199 2018
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 AlteredExpression disease BEFREE Computational analysis indicated that miR-296-3p targeted PTEN, which regulates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway and PTEN is involved in the carcinogenesis of SCC. miR-296-3p directly regulated PTEN expression in head and neck cancer cells, with PTEN protein levels decreased in 4/19 the SCCs (21.0%), as compared with those in the IPs (76.4%). 28693263 2017
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 AlteredExpression disease BEFREE These observations suggest that TrkB is a promising target for future intervention strategies to prevent tumor metastasis, EMT program in laryngeal cancer.What is already known about this subject?• Cancer of the larynx is one of the most common types of head and neck cancer.• The survival rate of advanced laryngeal cancer is only 30 to 40%.• The tropomyosin-related kinase B receptor (TrkB), together with TrkA and TrkC, are neurotrophin receptors regulating the proliferation and differentiation of neuronal cells.What are the new findings?• TrkB are overexpressed in laryngeal cancer.• TrkB signaling is involved in tumorigenicity of laryngeal cancer.• TrkB acts as a key regulator of the PI3K/AKT signal pathway-mediated tumor metastasis.How might these results change the focus of research or clinical practice?• These observations suggest that TrkB is a promising target for future intervention strategies to prevent tumor metastasis, EMT program in laryngeal cancer. 29312563 2017
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 Biomarker disease BEFREE Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. 28197389 2017
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 Biomarker disease BEFREE Our findings reveal a new mechanism by which EGFR/PI3K/Akt/mTOR signaling promotes head and neck cancer progression and underscores the need for developing a therapeutic strategy for targeting IKK/NF-κB either as a single agent or in combination with cisplatin in head and neck cancer. 26895469 2016
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 Biomarker disease BEFREE The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. 24219320 2015
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 Biomarker disease BEFREE Inhibition of the PI3K/Akt pathway decreases hypoxia within SQ20B human head and neck cancer xenografts. 25995437 2015
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 Biomarker disease BEFREE Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. 23619167 2013
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 AlteredExpression disease BEFREE PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. 23640975 2013
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 Biomarker disease BEFREE Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets. 23847349 2013
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.400 CausalMutation disease CGI